Astellas Pharma (4503) Q4 2025 earnings summary

Executive summary

• FY2024 achieved record-high revenue and core operating profit, with revenue up 19.2% and core operating profit up 41.7% year-over-year, driven by strong growth in strategic brands and cost optimization initiatives.

• Strategic brands (PADCEV, IZERVAY, VEOZAH, VYLOY, XOSPATA) more than doubled sales to nearly ¥340 billion, significantly contributing to profit growth and robust expansion across all regions.

• Cost optimization through the Sustainable Margin Transformation (SMT) program achieved ¥40 billion in savings, improving the SG&A ratio by 3.1 percentage points and reallocating resources to growth investments.

• U.S. revenue grew 30.7%, while Japan saw a 1.2% decline; all other regions posted double-digit growth.

• The company anticipates continued strong momentum in FY2025, with strategic brands expected to drive further revenue and profit growth.

Financial highlights

• FY2024 revenue reached ¥1,912.3 billion, up 19.2% year-over-year; core operating profit was ¥392.4 billion, up 41.7%; core OP margin improved by 3.3 percentage points to 20.5%.

• Operating profit rose to ¥41 billion, up 60.8%, and net profit increased to ¥50.7 billion, up 197.7% year-over-year.

• SG&A expenses were ¥843.0 billion (+13.9% YoY); R&D expenses ¥327.7 billion (+11.4% YoY).

• Forex had a positive impact of ¥68.1 billion on revenue and ¥15.1 billion on core operating profit.

• Free cash flow turned positive at ¥105.1 billion (vs. -¥673.3 billion in FY2023); equity ratio improved to 45.3%.

Outlook and guidance

• FY2025 revenue is forecast at ¥1,930.0 billion (+0.9% YoY), with underlying sales (excluding forex) expected to grow 7%.

• Core operating profit is projected at ¥410.0 billion (+4.5% YoY), with a margin of 21.2%.

• Dividend per share is forecast to increase by ¥4 to ¥78.

• Strategic brands are expected to reach ¥470 billion in sales, a 40% year-over-year increase.

• Full basis profit for FY2025 forecasted at ¥130.0 billion (+156.2%), with basic EPS at ¥72.61.